184 related articles for article (PubMed ID: 36082904)
1. Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors.
Jardim DLF; Millis SZ; Ross JS; Lippman S; Ali SM; Kurzrock R
Oncologist; 2023 Feb; 28(2):e82-e91. PubMed ID: 36082904
[TBL] [Abstract][Full Text] [Related]
2. Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions.
Jardim DL; Millis SZ; Ross JS; Woo MS; Ali SM; Kurzrock R
Oncologist; 2021 Jan; 26(1):e78-e89. PubMed ID: 32885893
[TBL] [Abstract][Full Text] [Related]
3. Targeting the FGF/FGFR axis and its co-alteration allies.
Uehara Y; Ikeda S; Kim KH; Lim HJ; Adashek JJ; Persha HE; Okamura R; Lee S; Sicklick JK; Kato S; Kurzrock R
ESMO Open; 2022 Dec; 7(6):100647. PubMed ID: 36455506
[TBL] [Abstract][Full Text] [Related]
4. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
[TBL] [Abstract][Full Text] [Related]
5. Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics.
Jardim DL; Millis SZ; Ross JS; Woo MS; Ali SM; Kurzrock R
Oncologist; 2021 Apr; 26(4):e715-e718. PubMed ID: 33522043
[TBL] [Abstract][Full Text] [Related]
6. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics.
Parish A; Schwaederle M; Daniels G; Piccioni D; Fanta P; Schwab R; Shimabukuro K; Parker BA; Helsten T; Kurzrock R
Cell Cycle; 2015; 14(13):2121-8. PubMed ID: 25950492
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
10. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
[TBL] [Abstract][Full Text] [Related]
11. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of FGFR Alteration Status in Urothelial Tumors.
Bahlinger V; Eckstein M; Hartmann A; Stöhr R
Methods Mol Biol; 2023; 2684():283-291. PubMed ID: 37410241
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
[TBL] [Abstract][Full Text] [Related]
16. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma.
Necchi A; Madison R; Pal SK; Ross JS; Agarwal N; Sonpavde G; Joshi M; Yin M; Miller VA; Grivas P; Chung JH; Ali SM
Eur Urol Focus; 2021 Nov; 7(6):1339-1346. PubMed ID: 32861617
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor (
Al-Obaidy KI; Cheng L
J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
[TBL] [Abstract][Full Text] [Related]
19. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Ascione CM; Napolitano F; Esposito D; Servetto A; Belli S; Santaniello A; Scagliarini S; Crocetto F; Bianco R; Formisano L
Cancer Treat Rev; 2023 Apr; 115():102530. PubMed ID: 36898352
[TBL] [Abstract][Full Text] [Related]
20. Genomic Characterization of Upper Tract Urothelial Carcinoma.
Sfakianos JP; Cha EK; Iyer G; Scott SN; Zabor EC; Shah RH; Ren Q; Bagrodia A; Kim PH; Hakimi AA; Ostrovnaya I; Ramirez R; Hanrahan AJ; Desai NB; Sun A; Pinciroli P; Rosenberg JE; Dalbagni G; Schultz N; Bajorin DF; Reuter VE; Berger MF; Bochner BH; Al-Ahmadie HA; Solit DB; Coleman JA
Eur Urol; 2015 Dec; 68(6):970-7. PubMed ID: 26278805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
